Skip to content
Search

Latest Stories

High-dispensing pharmacy sold after 50 years, Matrix Pharmacy offloads off-patch branch

High-dispensing pharmacy sold after 50 years, Matrix Pharmacy offloads off-patch branch

A first-time buyer has taken over Bishop Waltham Pharmacy, previously owned by Matrix Primary Healthcare Ltd.

Christie & Co, a specialist business property adviser, recently finalised the sale of two pharmacies—one located in Wales and the other in Hampshire.

Sylvia Williams Chemist, a well-performing community pharmacy located on the main high street of the Vale of Glamorgan market town of Cowbridge, has been sold after an impressive 50 years of ownership.


Dispensing an average of 12,500 items monthly, the business has been owned by Kate Thomas and her family for nearly 50 years. It was put on the market to enable her retirement and allow her to focus on other interests, the broker said.

The pharmacy has been purchased by Zaid Salih, making it his second pharmacy acquisition.

Jonathan Board, Director – Medical at Christie & Co, who handled the sale, said that Sylvia Williams Chemist attracted a wide range of buyers.

He said that pharmacies with “a healthy level of prescriptions, a good level of footfall, and space for the delivery of additional services” are currently in demand, and it was one of them.

“Despite ongoing operational challenges in the marketplace, it is showing remarkable resilience and there remains significant demand for well-established and well-located pharmacies such as this one,” he added.

Bishop Waltham Pharmacy near Southampton Hampshire Photo credit: Christie & Co

In a separate transaction, a first-time buyer has acquired Bishops Waltham Pharmacy near Southampton, Hampshire.

Previously owned by multi-operator, Matrix Primary Healthcare Ltd., this well-established community pharmacy provides NHS and private services, dispensing an average of 6,200 items per month.

Following a confidential sales process, the pharmacy has been sold to Madhu Bhogadi, an experienced local pharmacist embarking on his first venture into pharmacy ownership.

Akwal Singh, Director at Matrix Pharmacy Healthcare Ltd, shared that it took them some time to decide to market one of their off-patch pharmacies, as they hadn't sold a business in many years.

“We were fortunate to attract strong interest in the pharmacy from the start, and I'm delighted with how things went. We're extremely pleased with the outcome and do not doubt that Madhu will be able to take the business to new heights,” he said.

Bhogadi, the new owner of Bishops Waltham Pharmacy, is looking forward to growing the business over time, aiming to make it an integral part of the local community for many years and to truly make it his own.

Jonathan noted that currently, the majority of active buyers are independent operators seeking well-established pharmacies that could benefit from renewed enthusiasm and energy.

 

 

 

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less